News Archive

2020

May

Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

Read More
Media Release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Read More
Media Release / May 06, 2020

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Read More

April

Media Release / Apr 30, 2020

Novartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities

Read More
Media Release / Apr 03, 2020

Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund

Read More

March

Media Release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 18, 2020

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Read More
Media Release / Mar 18, 2020

Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements

Read More

February

Media Release / Feb 11, 2020

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

Read More

Related Links